DE602005012097D1 - Adjuvante zusammensetzung und anwendungsverfahren dafür - Google Patents

Adjuvante zusammensetzung und anwendungsverfahren dafür

Info

Publication number
DE602005012097D1
DE602005012097D1 DE602005012097T DE602005012097T DE602005012097D1 DE 602005012097 D1 DE602005012097 D1 DE 602005012097D1 DE 602005012097 T DE602005012097 T DE 602005012097T DE 602005012097 T DE602005012097 T DE 602005012097T DE 602005012097 D1 DE602005012097 D1 DE 602005012097D1
Authority
DE
Germany
Prior art keywords
adjuvant composition
vaccine
application therefor
gammadeltat
directed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602005012097T
Other languages
German (de)
English (en)
Inventor
Jerome Tiollier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innate Pharma SA
Original Assignee
Innate Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma SA filed Critical Innate Pharma SA
Publication of DE602005012097D1 publication Critical patent/DE602005012097D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DE602005012097T 2004-04-26 2005-04-25 Adjuvante zusammensetzung und anwendungsverfahren dafür Expired - Lifetime DE602005012097D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56495904P 2004-04-26 2004-04-26
US62906904P 2004-11-18 2004-11-18
PCT/IB2005/001485 WO2005102385A1 (en) 2004-04-26 2005-04-25 Adjuvant composition and methods for its use

Publications (1)

Publication Number Publication Date
DE602005012097D1 true DE602005012097D1 (de) 2009-02-12

Family

ID=34969994

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005012097T Expired - Lifetime DE602005012097D1 (de) 2004-04-26 2005-04-25 Adjuvante zusammensetzung und anwendungsverfahren dafür

Country Status (8)

Country Link
US (1) US20070218086A1 (enExample)
EP (1) EP1761278B1 (enExample)
JP (1) JP2007534743A (enExample)
AT (1) ATE419008T1 (enExample)
AU (1) AU2005235271A1 (enExample)
CA (1) CA2564562A1 (enExample)
DE (1) DE602005012097D1 (enExample)
WO (1) WO2005102385A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0212666D0 (en) * 2002-05-31 2002-07-10 Secr Defence Immunogenic sequences
US20070134273A1 (en) * 2004-02-10 2007-06-14 Francois Romagne Composition and method for the treatment of carcinoma
WO2006067635A2 (en) * 2004-12-20 2006-06-29 Innate Pharma S.A. USE OF Ϝδ T LYMPHOCYTE ACTIVATORS AS VACCINE ADJUVANT
BRPI0608926A2 (pt) * 2005-03-22 2010-11-03 Innate Pharma ativador de células t gamadelta, composição farmacêutica, uso de um ativador de células t gamadelta, composição de vacina, método de ativação de uma célula t gamadelta, célula t gamadelta, e, uso de uma célula t gamadelta
GB2443591B (en) * 2005-09-07 2010-04-28 Secr Defence Adjuvanted vaccine
ITMI20060366A1 (it) * 2006-03-01 2007-09-02 C4T S C A R L Composti organo tiopirosfosfati metodo per prepararli e composizioni che li contengono
EP1878440A1 (en) * 2006-07-13 2008-01-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta cell activator compounds
WO2008012538A2 (en) * 2006-07-25 2008-01-31 The Secretary Of State For Defence Live vaccine strains of francisella
EP2123285A1 (en) * 2008-05-21 2009-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Nucleosidic phosphoantigens for use in VGAMMA9DELTA2 T cell-mediated therapy
US8735624B2 (en) 2008-09-10 2014-05-27 Innate Pharma Polymorphic form of CHDMAPP, method of preparation thereof, and pharmaceutical composition comprising same
CA2738769C (en) * 2008-09-29 2016-02-09 Cadila Pharmaceuticals Ltd. Farnesoid-x-receptor antagonist as a vaccine adjuvant
GB0901411D0 (en) * 2009-01-29 2009-03-11 Secr Defence Treatment
US10226528B2 (en) 2013-03-15 2019-03-12 The Trustees Of The University Of Pennsylvania Vaccines with biomolecular adjuvants
KR102451441B1 (ko) * 2020-06-25 2022-10-12 대한민국 신규 면역증강제 및 이를 포함하는 백신 조성물
CN115916255A (zh) * 2020-06-26 2023-04-04 大韩民国(动植物检疫局) 新型免疫刺激剂和包含其的疫苗组合物
IL309249A (en) * 2021-06-28 2024-02-01 Byondis Bv Conjugates including phosphoantigens and their use in therapy
GB202114311D0 (en) * 2021-10-06 2021-11-17 Molecular Attraction Ab New compositions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8913737D0 (en) 1989-06-15 1989-08-02 Univ Birmingham A novel anti-allergy treatment
US5639653A (en) 1993-07-19 1997-06-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva Universtiy Method for proliferating Vγ2Vδ2 T cells
US5688506A (en) 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
WO1998050567A1 (en) 1997-05-02 1998-11-12 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
BE1011282A3 (fr) * 1997-07-14 1999-07-06 Solvay Composition a base de polyethylene et procede de fabrication d'objets faconnes a partir de la composition.
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
FR2782722B1 (fr) * 1998-09-01 2001-01-12 Inst Nat Sante Rech Med Nouveaux composes phosphoepoxydes, procede de fabrication et applications
FR2782721B1 (fr) 1998-09-01 2000-11-03 Inst Nat Sante Rech Med Nouveaux composes phosphohalohydrines, procede de fabrication et applications
WO2003009855A2 (de) * 2001-07-20 2003-02-06 Bioagency Ag Organo-phosphorverbindungen zur aktivierung von gamma/delta-t-zellen
EP1434859A2 (en) 2001-07-25 2004-07-07 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
WO2003038072A1 (en) * 2001-10-31 2003-05-08 Universite Libre De Bruxelles Generation and use of new types of dendritic cells
FR2833266B1 (fr) 2001-12-11 2004-10-22 Mayoly Spindler Lab Nouveaux derives phosphonates, leur procede de preparation, leur utilisation comme modulateurs de l'activite des lymphocytes tgamma9 delta2
ATE441420T1 (de) 2002-12-02 2009-09-15 Innate Pharma Interleukin-2 und gamma delta t zellaktivator enthaltende zusammensetzungen und deren verwendungen
WO2005021708A2 (en) * 2003-05-16 2005-03-10 University Of Maryland Biotechnology Institute Bisphosphonates for prophylaxis and therapy against bioterrorism agents
BRPI0417088A (pt) 2003-12-02 2007-03-13 Innate Pharma ativador de célula t gama delta, composição farmacêutica, uso do ativador de célula t gama delta, composição de vacina, métodos para preparar um composto, e para ativar uma célula t gama delta, célula t gama delta, e, uso da mesma

Also Published As

Publication number Publication date
US20070218086A1 (en) 2007-09-20
ATE419008T1 (de) 2009-01-15
AU2005235271A1 (en) 2005-11-03
EP1761278A1 (en) 2007-03-14
EP1761278B1 (en) 2008-12-31
WO2005102385A1 (en) 2005-11-03
JP2007534743A (ja) 2007-11-29
CA2564562A1 (en) 2005-11-03

Similar Documents

Publication Publication Date Title
DE602005012097D1 (de) Adjuvante zusammensetzung und anwendungsverfahren dafür
EA200800812A1 (ru) Композиции антитела против cd3
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
ATE426412T1 (de) Adjuvante influenza-vakzine
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
CY1112277T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
MX358705B (es) Agentes de union de esclerostina.
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
NO20071604L (no) Loxapinanaloger og fremgangsmater for anvendelse derav.
EA200801427A1 (ru) Молекулы антитела со специфической активностью в отношении интерлейкина-6 (ил-6) человека
DE602004028468D1 (de) Haltung von immunantworten gegen mhc-klasse-i-beschränkte epitope, für prophylaktische oder therapeutische zwecke
AR057253A1 (es) Anticuerpos anti-ox40l y metodos que los utilizan
CR20180142A (es) ANTICUERPOS ANTI-FAP Y MÉTODOS DE USO(Divisional Exp: 2013-0038)
NO20074238L (no) Fiksert dosering av HER-antistoffer
AR061246A1 (es) Anticuerpos anti- dill4 y metodos que los usan
DK1668001T3 (da) Substituerede heteroarylbenzofuransyrer
BRPI0513144A (pt) certos compostos de fosfato de glucosaminida de aminoalquila e seu uso
NO20071937L (no) Fremgangsmater og mellomprodukter for fremstilling av cysteinproteaseinhibitorer
MX2007002787A (es) Adyuvante de glicosilceramida para antigenos de sacarido.
EA200701305A1 (ru) Иммуногенные композиции, содержащие циклические пептиды, полученные из бета-амилоидного пептида
AR059851A1 (es) Anticuerpos de la egfl7 y metodos de uso
WO2006067635A3 (en) USE OF Ϝδ T LYMPHOCYTE ACTIVATORS AS VACCINE ADJUVANT
NO20062579L (no) Preparater som omfatter melittin-avledede peptider og fremgangsmate for styrking av immunresponser mot malantigener
EA200702092A1 (ru) Липосомная композиция для индукции иммунитета
EA201200538A1 (ru) Арабиногалактан для повышения приобретенного иммунного ответа

Legal Events

Date Code Title Description
8364 No opposition during term of opposition